An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2
LP Courtney, JL Phelps, LM Karavodin - Immunopharmacology, 1994 - Elsevier
We examined the ability of anti-human recombinant interleukin-2 (hu rIL-2) monoclonal
antibody DMS-1.10 to increase serum half-life of hu rIL-2, and the effect of this complex on
inhibition of tumor progression in a B16-F10 murine melanoma model. In C57B1/6 mice,
intravenous (iv) injection of DMS-1.10 premixed with 1× 10 4 units (U) of hu rIL-2 at a 1: 1
molar ratio extended serum half-life greater than 10-fold (222 min) when compared to the
same dose of hu rIL-2 alone (20 min). In a murine tumor model, multiple intraperitoneal (ip) …
antibody DMS-1.10 to increase serum half-life of hu rIL-2, and the effect of this complex on
inhibition of tumor progression in a B16-F10 murine melanoma model. In C57B1/6 mice,
intravenous (iv) injection of DMS-1.10 premixed with 1× 10 4 units (U) of hu rIL-2 at a 1: 1
molar ratio extended serum half-life greater than 10-fold (222 min) when compared to the
same dose of hu rIL-2 alone (20 min). In a murine tumor model, multiple intraperitoneal (ip) …